A Study of TAK-279 in Adults With or Without Liver Damage
Status:
Recruiting
Trial end date:
2024-08-08
Target enrollment:
Participant gender:
Summary
The main aim of this study is to find out how the body processes 1 dose of TAK-279
(pharmacokinetics) in participants with liver problems compared to participants without liver
problems. Other aims are to check for side effects from TAK-279 and to learn how well
participants tolerate 1 dose of TAK-279.
The participants will need to stay at the clinic for 11 days.